Hide fields
Filter
Group
Sort
Name
1
Unity Biotechnology
2
Oisin Biotechnologies
3
Senolytic Therapeutics
4
FoxBio
5
Cleara Biotech
6
Rubedo Life Science
7
Dorian Therapeutics
8
Deciduous Therapeutics
9
SIWA Therapeutics
10
Atropos Therapeutics
11
Senisca
12
Numeric Biotech
13
Rejuversen
14
Oncoscence
Drag to adjust the number of frozen columns
Inception
Description
Stage
Expected Start Clinical Trials
Modality
Class
Pathway / Biomarker
Indications
Founders
Total Funding, Venture (M)
Funding Stage
Notes
Slide Decks
Funding
Funding 2
Investors
2011
small molecule drugs targeting Bcl-xL.
Phase 1
Present
small molecule drug
senolytic
Bcl-xL
Diabetic Macular Edema
Age-related Macular Degeneration
Diabetic Retinopathy
Neurological disease
Nathaniel David
Judith Campisi
Jan van Deursen
Daohong Zhou
$210.00
IPO
ARCH Venture Partners
Longevity Fund
2014
systemic delivery of p16-induced suicide genes
Preclinical
2022+
gene therapy
senolytic
p16
Kidney disease
Matt Scholz
Gary Hudson
$5.00
Seed
2017
senomorphic and senolytic drugs. A Life Biosciences daughter company
Preclinical
small molecule drug
senolytic
senomorphic
immunotherapy
beta-galactosidase
Fibrotic disease
Kidney disease
Lung disease
Manuel Serrano
Marc Ramic Castelltort
Seed
2018
FOXO4-p53 small molecule drugs. Joint venture between Ichor Therapeutics and Juvenescence
Preclinical
2021
small molecule drug
senolytic
FOXO4-p53
Osteoarthritis
Aging
Kelsey Moody
$10.00
Seed
7/12/2018
Juvenescence
2018
Developing a more selective version of the FOXO4-DRI peptide
Preclinical
peptide
senolytic
FOXO4-p53
Cancer
Sarcopenia
Peter de Keizer
Tobias Madl
Marco Demaria
$0.30
Seed
2018
Developing galacto-conjugate senolytic prodrugs?
Preclinical
2022
small molecule drug
senolytic
SA-beta-galactosidase
IPF
COPD
Cancer
Sarcopenia
Frailty
Marco Quarta
$12.00
Seed
12/3/2020
2018
Developing senoblockers for age-related disease and CAR-T products
Preclinical
small molecule drug
senomorphic
USP16
Osteoarthritis
CAR-T cell viability
Maddalena Adorno
Benedetta di Robilant
Seed
2018
Immunotherapy x senolysis
Preclinical
small molecule drug
immunotherapy
senolytic
Bcl-2
T1 Diabetes
Anil Bhushan
Robin Mansukhani
$5.80
Seed
2006
Monoclonal antibody that targets senescent cells. Immunotherapeutic approach.
Preclinical
monoclonal antibody
immunotherapy
senolytic
glycation end product antigen
Cancer
Lewis Gruber
Misty Gruber
$1.60
Seed
2019
Senosupressor that prevents the transtion from cell quiescence to cell senescence.
Preclinical
small molecule drug
senosupressor
senostimulator
ATRX foci
Cancer
Andrew Koff
William Tap
$0.33
Seed
10/12/2018
2020
RNA therapies to rejuvenate senescent cells via splicing factors..
Preclinical
2024+
small molecule drug
senomorphic
RNA splicing factor genes
IPF
Skin-aging
Lorna Harries
Seed
2017
FOXO4-DRI peptide.
Preclinical
Q2 2021
peptide
senolytic
FOXO4-p53
Neurological disease
autoimmune disease
Seed
2020
PD-L2 inhibitor to recruit immune system to clear senescent cells involved in cancer / chemotherapy.
Preclinical
2023+
monoclonal antibody
senolytic
immunotherapy
PD-L2
Cancer
Manuel Serrano
Marc Ramic Castelltort
Tim Cash
Seed
2019
Combination therapy: Induce senescence in tumours followed by a targeted senolytic.
Preclinical
small molecule drug
senolytic
senostimulator
Cancer
Seed
14 records
Summary
Summary
Summary
Summary
Summary
Summary
Summary
Summary
Summary
Summary
Sum
$245.03
Summary
Summary
Summary
Summary
Summary
Summary
Alert
Lorem ipsum